Abiomed (ABMD) – StreetInsider.com Reports
-
Johnson & Johnson (JNJ) closes acqusition of Abiomed
-
Abiomed (ABMD) Announces FDA Approval of Impella ECP Heart Pump
-
Steel Dynamics (STLD) to be added to S&P 500, Super Micro (SMCI) to S&P MidCap 400
-
Sanofi shares rise after French drugmaker ditches Horizon deal talks
-
Today's Most Important Upgrades
-
Morgan Stanley Upgrades ABIOMED (ABMD) to Equalweight
-
Deutsche Bank Downgrades ABIOMED (ABMD) to Hold
-
Today's Most Important Downgrades
-
Midday Movers: Uber Technologies, Intuit, Abiomed and More
-
William Blair Downgrades ABIOMED (ABMD) to Market Perform
-
Abiomed (ABMD) option implied decreases after Johnson & Johnson (JNJ) buying
-
Johnson & Johnson's (JNJ) $16.6bn Deal for Abiomed (ABMD) Deal a Positive - Stifel
-
Piper Sandler Downgrades ABIOMED (ABMD) to Neutral
-
Uber, Pfizer, Tesla, Carvana Rise Premarket; Eli Lilly Falls
-
Abiomed (ABMD) option implied flat into Johnson & Johnson (JNJ) buying
-
J&J to buy heart pump maker Abiomed for $16.6 billion ahead of consumer health spinoff
-
Johnson & Johnson (JNJ) Acquires Abiomed (ABMD) for $380/sh or $16.6B, Plus CVR Worth Up to $35/sh
-
Abiomed (ABMD) Announces FDA Approval of Impella RP Flex with SmartAssist
-
Abiomed (ABMD) Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
-
Abiomed (ABMD) Announces U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath
-
Mizuho Securities Starts ABIOMED (ABMD) at Buy
-
ABIOMED (ABMD) PT Lowered to $350 at Piper Sandler
-
Abiomed (ABMD) Announces Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
-
Abiomed (ABMD) Announces FDA Approval of RECOVER IV Trial with Exception from EFIC
-
Abiomed (ABMD) Tops Q1 EPS by 19c
-
ABIOMED (ABMD) PT Lowered to $355 at Deutsche Bank
-
Nephron Starts ABIOMED (ABMD) at Hold
-
Deutsche Bank Said April is Off to a Strong Start for ABIOMED (ABMD)
-
Abiomed (ABMD) Tops Q4 EPS by 7c
-
Abiomed (ABMD) Announces World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
-
Wolfe Research Starts ABIOMED (ABMD) at Peerperform
-
ABIOMED (ABMD) HF Portfolio Could Reach $17B - Piper Sandler
-
Abiomed (ABMD) Tops Q3 EPS by 16c; Raises Low End of FY Revenues Guidance
-
Abiomed (ABMD) Announces Approval of Impella 5.5 With SmartAssist in Japan and Hong Kong, US FDA Grants Impella BTR Conditional IDE Approval
-
Abiomed (ABMD) Tops Q2 EPS by 6c
-
ABIOMED (ABMD) Physician Survey - Jefferies
-
Abiomed's (ABMD) Impella ECP Granted FDA Breakthrough Device Designation
-
ABIOMED (ABMD) PT Raised to $410 at Deutsche Bank
-
ABIOMED (ABMD) Data Indicates a Coming Beat/Raise - Jefferies
-
Abiomed (ABMD) Right Heart Failure Pump Gains FDA Pre-Market Approval
-
ABIOMED (ABMD) NDR Conveys Confidence in Near Term Business Recovery, Piper Sandler Reiterates Buy
-
UPDATE: Deutsche Bank Starts ABIOMED (ABMD) at Buy, 'Size Matters'
-
ABIOMED (ABMD) Impella Data Shows a Sharp Rebound in April - Jefferies
-
Abiomed (ABMD) Acquires preCARDIA
-
Align Technology (ALGN) is a Value Play, Reiterated as Stifel Top Dental Pick
-
Abiomed (ABMD) Sees Early Weakness on Potential Competitive Device
-
Abiomed (ABMD) Tops Q4 EPS by 1c
-
Abiomed (ABMD) Announces Dr. Paula A. Johnson to Board
-
Abiomed (ABMD) Adds Myron Rolle, MD to Board
-
ABIOMED (ABMD) PT Raised to $425 at Jefferies After Earnings
Back to ABMD Stock Lookup